Comments on “Safety and efficacy of single pass versus multipass emission with 755 alexandrite laser for all‐skin‐type hair removal: a pilot study”

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Victor Gabriel Clatici ◽  
Cristiana Voicu ◽  
Elena Barinova ◽  
Mihai Lupu ◽  
Alin Laurentiu Tatu
Keyword(s):  
Pilot Study ◽  
Skin Type ◽  
Hair Removal ◽  
Alexandrite Laser ◽  
Safety And Efficacy ◽  
Single Pass

Effect of Wax Epilation Before Hair Removal With a Long-Pulsed Alexandrite Laser: A Pilot Study

2003 ◽  
Vol 29 (2) ◽  
pp. 118-123 ◽  
Author(s):  
Michael S. Lehrer ◽  
Glen H. Crawford ◽  
Joel M. Gelfand ◽  
James J. Leyden ◽  
Carmela C. Vittorio
Keyword(s):  
Pilot Study ◽  
Hair Removal ◽  
Alexandrite Laser

scholarly journals Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e048541
Author(s):  
Anna-Maria Hoffmann-Vold ◽  
Håvard H Fretheim ◽  
Vikas K Sarna ◽  
Imon Barua ◽  
Maylen N Carstens ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Pilot Study ◽  
Phase Ii ◽  
Intestinal Microbiome ◽  
Induction Phase ◽  
Inflammatory Disorder ◽  
Faecal Microbiota ◽  
Safety And Efficacy ◽  
Faecal Microbiota Transplantation ◽  
Patient Reported

IntroductionIn the multisystem inflammatory disorder systemic sclerosis (SSc), gastrointestinal tract (GIT) affliction is highly prevalent. There are no known disease modifying therapies and the negative impact is substantial. Aiming for a new therapeutic principle, and inspired by recent work showing associations between gut microbiota changes and GIT symptoms in SSc, we performed a pilot study on faecal microbiota transplantation (FMT) with the single-donor bacterial culture ‘Anaerobic Cultivated Human Intestinal Microbiome (ACHIM)’. Motivated by positive pilot study signals, we designed the ReSScue trial as a phase II multicentre, placebo-controlled, randomised 20-week trial to evaluate safety and efficacy on lower GIT symptoms of FMT by ACHIM in SSc.Methods and analysesWe aim to include 70 SSc participants with moderate to severe lower GIT symptoms, defined by the validated patient-reported University of California Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 2.0 questionnaire. The trial includes three parts. In part A1 (induction phase) lasting from week 0 to week 12, participants will be randomised 1:1 to repeat infusions of 30 mL ACHIM or placebo at week 0 and 2 by gastroduodenoscopy. In part A2, which is an 8-week subsequent maintenance phase, all study participants will receive 30 mL ACHIM at week 12 and followed until week 20 on continued blind. In part B, which will last until the last participant completes part A2, the participants will be followed through a maximum 16-week extended monitoring period, for longer-term data on safety and intervention effects. Primary endpoint is change from baseline to week 12 in UCLA GIT subscale scores of diarrhoea or bloating, depending on the worst symptom at baseline evaluated separately for each patient. Secondary endpoints are safety measures and changes in UCLA GIT scores (total, diarrhoea and bloating).Ethics and disseminationThis protocol was approved by the Northern Norwegian Committee for Medical Ethics. Study findings will be published.Trial registration numberNCT04300426; Pre-results.Protocol versionV.3.1.

scholarly journals Ocular injuries secondary to alexandrite laser-assisted hair removal

2017 ◽  
Vol 52 (2) ◽  
pp. e71-e75 ◽  
Author(s):  
Mohammed S. Asiri ◽  
Majed Alharbi ◽  
Trad Alkadi ◽  
Marwan Abouammoh ◽  
Mohammed Al-Amry ◽  
...  
Keyword(s):  
Hair Removal ◽  
Alexandrite Laser ◽  
Ocular Injuries

Comparing 18- Versus 12-mm Spot Size in Hair Removal Using a Gentlease 755-nm Alexandrite Laser

2004 ◽  
Vol 30 (4) ◽  
pp. 494-497 ◽  
Author(s):  
Keyvan Nouri ◽  
Halland Chen ◽  
Sogol Saghari ◽  
Carlos A. Ricotti
Keyword(s):  
Spot Size ◽  
Hair Removal ◽  
Alexandrite Laser
Sign in / Sign up

Export Citation Format

Share Document